Literature DB >> 27704183

Autoimmune arthritis deteriorates bone quantity and quality of periarticular bone in a mouse model of rheumatoid arthritis.

T Shimizu1, M Takahata2, H Kimura-Suda3, Y Kameda1, K Endo1,4, H Hamano1, S Hiratsuka1, M Ota1, D Sato1, T Ito3, M Todoh4, S Tadano4, N Iwasaki1.   

Abstract

This study showed that autoimmune arthritis induces especially severe osteoporosis in the periarticular region adjacent to inflamed joints, suggesting that arthritis increases the fragility fracture risk near inflamed joints, which is frequently observed in patients with RA.
INTRODUCTION: Periarticular osteoporosis near inflamed joints is a hallmark of early rheumatoid arthritis (RA). Here we show that rheumatic inflammation deteriorates the bone quality and bone quantity of periarticular bone, thereby decreasing bone strength and toughness in a mouse model of RA.
METHODS: Female BALB/c mice and SKG mice, a mutant mouse model of autoimmune arthritis on the BALB/c background, were used. At 12 weeks of age, BALB/c mice underwent either Sham surgery or bilateral ovariectomy (OVX), and SKG mice underwent intraperitoneal injection of mannan to induce arthritis. Eight weeks later, the mice were killed and the femurs and tibias were subjected to micro-computed tomography, Fourier transform infrared (FTIR) spectroscopic imaging, X-ray diffraction, histology, and mechanical testing.
RESULTS: SKG mice developed significant trabecular bone loss in both the distal metaphysis of the femur and the lumbar vertebral body, but the extent of the bone loss was more severe in the distal metaphysis. Neither SKG nor OVX mice exhibited changes in the geometry and matrix properties of the diaphysis of the femur, whereas SKG mice, but not OVX mice, did exhibit changes in these properties in the distal metaphysis of the femur. Bone strength and fracture toughness of the distal metaphysis of the tibia adjacent to the inflamed ankle joint were significantly decreased in SKG mice.
CONCLUSIONS: Autoimmune arthritis induces periarticular osteoporosis, characterized by deterioration of cortical bone geometry and quality as well as by trabecular bone loss, leading to severe bone fragility in periarticular bone adjacent to inflamed joints.

Entities:  

Keywords:  Bone fragility; Bone quality; Cortical bone; Rheumatoid arthritis (RA)

Mesh:

Year:  2016        PMID: 27704183     DOI: 10.1007/s00198-016-3781-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  30 in total

Review 1.  Response of joint structures to inactivity and to reloading after immobilization.

Authors:  Kenneth D Brandt
Journal:  Arthritis Rheum       Date:  2003-04-15

2.  Comment on: periarticular osteoporosis: a useful feature in the diagnosis of early rheumatoid arthritis? Reliability and validity in a cross-sectional diagnostic study using dual-energy X-ray absorptiometry.

Authors:  Bruce Rothschild
Journal:  Rheumatology (Oxford)       Date:  2012-03-28       Impact factor: 7.580

3.  Dissociation of mineral and collagen orientations may differentially adapt compact bone for regional loading environments: results from acoustic velocity measurements in deer calcanei.

Authors:  John G Skedros; Scott M Sorenson; Yuichi Takano; Charles H Turner
Journal:  Bone       Date:  2006-02-03       Impact factor: 4.398

Review 4.  Epidemiology of adult rheumatoid arthritis.

Authors:  Yannis Alamanos; Alexandros A Drosos
Journal:  Autoimmun Rev       Date:  2005-03       Impact factor: 9.754

5.  Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency.

Authors:  P Ammann; R Rizzoli; J P Bonjour; S Bourrin; J M Meyer; P Vassalli; I Garcia
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

6.  Periarticular osteoporosis of the forearm correlated with joint destruction and functional impairment in patients with rheumatoid arthritis.

Authors:  T Iwata; H Ito; M Furu; M Hashimoto; T Fujii; M Ishikawa; N Yamakawa; C Terao; M Azukizawa; Y Hamamoto; T Mimori; H Akiyama; S Matsuda
Journal:  Osteoporos Int       Date:  2015-08-05       Impact factor: 4.507

7.  Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.

Authors:  T W Jensen; M S Hansen; K Hørslev-Petersen; L Hyldstrup; B Abrahamsen; B Langdahl; B Zerahn; J Pødenphant; K Stengaard-Petersen; P Junker; M Østergaard; T Lottenburger; T Ellingsen; L S Andersen; I Hansen; H Skjødt; J K Pedersen; U B Lauridsen; A J Svendsen; U Tarp; H Lindegaard; Anne Grethe Jurik; Aage Vestergaard; M L Hetland
Journal:  Ann Rheum Dis       Date:  2013-05-09       Impact factor: 19.103

8.  Influence of osteon area fraction and degree of orientation of HAp crystals on mechanical properties in bovine femur.

Authors:  Satoshi Yamada; Shigeru Tadano; Kazuhiro Fujisaki; Yuka Kodaki
Journal:  J Biomech       Date:  2012-10-22       Impact factor: 2.712

9.  Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis.

Authors:  A Gough; P Sambrook; J Devlin; A Huissoon; C Njeh; S Robbins; T Nguyen; P Emery
Journal:  J Rheumatol       Date:  1998-07       Impact factor: 4.666

10.  Bone formation and resorption are both increased in experimental autoimmune arthritis.

Authors:  Kresten Krarup Keller; Jesper Skovhus Thomsen; Kristian Stengaard-Pedersen; Frederik Dagnæs-Hansen; Jens Randel Nyengaard; Ellen-Margrethe Hauge
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

View more
  2 in total

1.  Rheumatoid arthritis and bone health.

Authors:  Shanze Ashai; Nicholas C Harvey
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

2.  Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis.

Authors:  Takako Suzuki; Yukio Nakamura; Hiroyuki Kato
Journal:  Ther Clin Risk Manag       Date:  2018-03-01       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.